GH Therapy in Chronic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Authors' conclusion
GH therapy demonstrated improvements in cardiac function, exercise capacity, and HF symptoms, along with a statistically significant trend toward improvements in hard endpoints. Event-driven trials are needed to validate these findings.
Study context
- Population
- Adults with heart failure (HF) in randomised, placebo-controlled trials (PubMed, Cochrane Library, ClinicalTrials.gov)17 studies
- Comparison
- GH therapy vs placebo
- Outcome
- Efficacy of GH therapy in HF
Methodological detailsplacebo-controlled trials, random-effects model, PRISMA
- Placebo-controlled trials
- Random-effects model
- PRISMA
Pooled result
As reported in the abstract
GH vs PlaceboRelative risk (95% CI)P value
Composite of death, worsening HF or ventricular tachycardia; reduced by 41% with GH
.59(0.39–0.90)
P = 0.013- New York Heart Association class; improved with GH
- −0.44 (95% CI −0.08 to −0.81); P = 0.023
Further pooled results
Subgroup analyses
- Greater benefits with ischemic cardiomyopathy, baseline ejection fraction ≥30% and longer treatment duration
Original publication
GH Therapy in Chronic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. Published 21 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →